LivaNova (NASDAQ:LIVN) and Vasamed (OTCMKTS:VSMD) Head-To-Head Comparison

Vasamed (OTCMKTS:VSMD) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations and price targets for Vasamed and LivaNova, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vasamed	0	0	0	0	0.00
LivaNova	0	4	6	1	2.73

LivaNova has a consensus target price of $81.38, suggesting a potential upside of 4.07%. Given LivaNova’s stronger consensus rating and higher possible upside, analysts clearly believe LivaNova is more favorable than Vasamed.

Profitability

This table compares Vasamed and LivaNova’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vasamed	N/A	N/A	N/A
LivaNova	7.48%	16.48%	7.59%

Insider & Institutional Ownership

97.6% of LivaNova shares are owned by institutional investors. 8.0% of Vasamed shares are owned by company insiders. Comparatively, 0.3% of LivaNova shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Vasamed and LivaNova”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vasamed	N/A	N/A	N/A	N/A	N/A
LivaNova	$1.39 billion	3.09	-$242.47 million	$1.95	40.10

Vasamed has higher earnings, but lower revenue than LivaNova.

Summary

LivaNova beats Vasamed on 9 of the 10 factors compared between the two stocks.

About Vasamed

Vasamed Incorporated designs, licenses, manufactures, and distributes products, software, and services for assessing and managing hemodynamic health in the United States. It offers SensiLase PAD-IQ, which supports skin perfusion pressure, pulse volume recording, and ankle brachial index calculation for Doppler-obtained pressures; and Wound Imaging & SmartDraw wound measurement systems. The company also provides PAD-IQ Studycast that provides rapid transmission of diagnostic tests to vascular specialist for interpretation of results and medically indicated therapeutic intervention; and custom carrying case to secure and protect the PAD-IQ system. It serves clinicians and patients. The company was founded in 1988 and is headquartered in Eden Prairie, Minnesota.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.